UniProtKB/SwissProt variant VAR

Variant information

Variant position:

34

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

Disease [Disclaimer]

The variants are classified into three categories: Disease, Polymorphism and Unclassified.

Disease: Variants implicated in disease according to literature reports.
Polymorphism: Variants not reported to be implicated in disease.
Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:

From Glycine (G) to Glutamate (E) at position 34 (G34E, p.Gly34Glu).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from glycine (G) to medium size and acidic (E)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Involvement in disease:

Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry is involved in disease pathogenesis.

The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:

In PTR.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs28931589 [ dbSNP | Ensembl ]

Sequence information

Variant position:

34

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

781

The length of the canonical sequence.

Location on the sequence:

MEPDRKAAVSHWQQQSYLDS G IHSGATTTAPSLSGKGNPEE

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEE

                              MEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEE

Mouse                         MEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEE

Rat                           MEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEE

Bovine                        MEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEE

Xenopus laevis                MEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPED

Zebrafish                     MDPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPED

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 781	Catenin beta-1
Modified residue	23 – 23	Phosphoserine; by GSK3-beta; alternate
Modified residue	29 – 29	Phosphoserine; by GSK3-beta
Modified residue	33 – 33	Phosphoserine; by GSK3-beta and HIPK2
Modified residue	37 – 37	Phosphoserine; by GSK3-beta and HIPK2
Modified residue	41 – 41	Phosphothreonine; by GSK3-beta
Modified residue	45 – 45	Phosphoserine
Modified residue	49 – 49	N6-acetyllysine
Glycosylation	23 – 23	O-linked (GlcNAc) serine; alternate
Mutagenesis	29 – 29	S -> F. No effect.

Literature citations

A common human skin tumour is caused by activating mutations in beta-catenin.
Chan E.F.; Gat U.; McNiff J.M.; Fuchs E.;
Nat. Genet. 21:410-413(1999)
Cited for: VARIANTS PTR GLY-32; TYR-32; PHE-33; TYR-33; GLU-34; CYS-37; PHE-37 AND ILE-41;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P35222: Variant p.Gly34Glu